Johnson & Johnson (JNJ) is a leading drug manufacturers—general business based in the US. It opened the day at USD$146 after a previous close of USD$146.42. During the day the price has varied from a low of USD$143.165 to a high of USD$146. The latest price was USD$143.23 (25 minute delay). Johnson & Johnson is listed on the NYSE and employs 132,200 staff. All prices are listed in US Dollars.
About our promoted products: Our 'promoted' products are presented as a result of a commercial advertising arrangement or to highlight a particular feature. Promoted products are not a recommendation, an indication a product is the best in its category, nor represent all products in the market. It is important to compare your options and find the right product for you. Some of our promoted products are CFD providers. CFDs are complex financial products and traders are at high-risk of losing all of or more than their initial investment
|52-week range||USD$106.9486 - USD$154.3971|
|50-day moving average||USD$145.3929|
|200-day moving average||USD$146.5855|
|Wall St. target price||USD$166.18|
|Dividend yield||USD$4.04 (2.76%)|
|Earnings per share (TTM)||USD$6.36|
|1 week (2020-11-16)||-5.05%|
|1 month (2020-10-23)||-1.38%|
|3 months (2020-08-21)||-6.24%|
|6 months (2020-05-22)||-0.79%|
|1 year (2019-11-22)||3.74%|
|2 years (2018-11-23)||0.70%|
|3 years (2017-11-22)||4.33%|
|5 years (2015-11-23)||39.37%|
Valuing Johnson & Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson & Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Johnson & Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Johnson & Johnson shares trade at around 23x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Johnson & Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.7211. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson & Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Johnson & Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$27.3 billion.
The EBITDA is a measure of a Johnson & Johnson's overall financial performance and is widely used to measure a its profitability.
There are currently 12.8 million Johnson & Johnson shares held short by investors – that's known as Johnson & Johnson's "short interest". This figure is 11.5% up from 11.5 million last month.
There are a few different ways that this level of interest in shorting Johnson & Johnson shares can be evaluated.
Johnson & Johnson's "short interest ratio" (SIR) is the quantity of Johnson & Johnson shares currently shorted divided by the average quantity of Johnson & Johnson shares traded daily (recently around 6.3 million). Johnson & Johnson's SIR currently stands at 2.02. In other words for every 100,000 Johnson & Johnson shares traded daily on the market, roughly 2020 shares are currently held short.
However Johnson & Johnson's short interest can also be evaluated against the total number of Johnson & Johnson shares, or, against the total number of tradable Johnson & Johnson shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Johnson & Johnson's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Johnson & Johnson shares in existence, roughly 0 shares are currently held short) or 0.0049% of the tradable shares (for every 100,000 tradable Johnson & Johnson shares, roughly 5 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Johnson & Johnson.
Steps to owning and managing Kandi shares, with 24-hour and historical pricing before you buy.
Steps to owning and managing Fisker shares, with 24-hour and historical pricing before you buy.
Steps to owning and managing GM shares, with 24-hour and historical pricing before you buy.
Steps to owning and managing Virgin Galactic shares, with 24-hour and historical pricing before you buy.
Steps to owning and managing XPEV, with 24-hour and historical pricing before you buy.
Steps to owning and managing Straker Translations shares from New Zealand.
Ever wondered how to buy shares in Workhorse Group? We explain how and compare a range of providers that can give you access to many brands, including the Workhorse Group.
Ever wondered how to buy shares in BBGI Sicav? We explain how and compare a range of providers that can give you access to many brands, including BBGI Sicav.
Ever wondered how to buy shares in A.O. Smith? We explain how and compare a range of providers that can give you access to many brands, including A.O. Smith.
Ever wondered how to buy shares in Estee Lauder? We explain how and compare a range of providers that can give you access to many brands, including Estee Lauder.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.